Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% for Macular Edema Prevention in Diabetics (Study 1)
NCT01853072Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of nepafenac in macular edema, sponsored by Alcon Inc.. Started Jun 2013; status: completed.
02
Drugs
nepafenac
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01853072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853072.